SynthesisClinical rheumatology2010
Off-label use of rituximab in systemic lupus erythematosus: a systematic review.
Synthesis in Clinical rheumatology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- The efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome: a meta-analysis.Scientific reports · 2015Pooled it
- Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis.Journal of Zhejiang University. Science. B · 2012Pooled it
- Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy.Modern rheumatology · 2016Trial
- [The LUNAR study: rituximab for lupus nephritis?].Zeitschrift fur Rheumatologie · 2013Trial
- B Cell Aberrance in Lupus: the Ringleader and the Solution.Clinical reviews in allergy & immunology · 2022Review
- [New treatments for systemic lupus erythematosus].Zeitschrift fur Rheumatologie · 2020Review
- Review
- Perioperative Management of Patients with Inflammatory Rheumatic Diseases Undergoing Major Orthopaedic Surgery: A Practical Overview.Advances in therapy · 2018Review
- Treatment of catastrophic antiphospholipid syndrome.Current opinion in rheumatology · 2016Review
- [Biologics therapy for systemic lupus erythematosus. Current situation].Zeitschrift fur Rheumatologie · 2015Review
- Rituximab and lupus--a promising pair?Current rheumatology reports · 2014Review
- Ethnic differences in DNA methyltransferases expression in patients with systemic lupus erythematosus.Journal of clinical immunology · 2013Article
- Resolve, revise, and relax: the 3 Rs of B cell repertoire adjustment.Immunology letters · 2012Review
- Multicenter retrospective analysis of the effectiveness and safety of rituximab in korean patients with refractory systemic lupus erythematosus.Autoimmune diseases · 2012Article
- Belimumab in systemic lupus erythematosus: an update for clinicians.Therapeutic advances in chronic disease · 2012Article
- Neuropsychiatric manifestations in systemic lupus erythematosus: epidemiology, pathophysiology and management.CNS drugs · 2011Review
- Neuropsychiatric systemic lupus erythematosus.Current neuropharmacology · 2011Article
- Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies.Current rheumatology reports · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Considerable interest in the efficacy of rituximab (a monoclonal CD20 antibody) in patients with systemic lupus erythematosus (SLE) has been generated due to its unique mode of action, culminating in a series of randomized and open trials, and case reports. However, this use is off-license and two significant RCTs have reported negative findings, reopening the debate on clinical benefit. This review of the available data suggests that rituximab induces B-cell depletion in 95% of patients, and a significant reduction in disease activity is achieved with a relatively good safety profile in patients with SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.